We recently published a list of 13 Best Cheap Dividend Stocks To Buy Right Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best cheap dividend stocks to buy right now.

Pfizer (PFE) stock gains as company appoints James List, a former J&J (JNJ) executive as Chief Internal Medicine Officer to lead R&D in obesity drugs. Read more here.

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the discount bin. It's no secret why Pfizer has not performed well recently. The company was never going to keep up those sales year in and year out.

The market sentiment in the next few months is likely to be quite positive for Pfizer. Read why I maintain my strong buy rating on PFE stock.

There is no better period, given the volatility in the markets today, to rotate assets into dividend stocks, said Steven Cress, VP of Quantitative Strategy at Seeking Alpha. During Seeking Alpha’s Dividend Investing Forum virtual event,

The general mood among these heavyweight investors is divided, with 48% leaning bullish and 37% bearish. Among these notable options, 5 are puts, totaling $799,839, and 22 are calls, amounting to $1,146,717.

In a report released today, Kerry Holford from Berenberg Bank maintained a Hold rating on Pfizer (PFE – Research Report), with a price target

(NYSE:PFE) shareholders, since the share price is down 43% in the last three years, falling well short of the market return of around 38%. While the last three years has been tough for Pfizer shareholders,

NEW YORK, February 24, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The